The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects
Open accessAbstract
OBJECTIVE—To evaluate whether homeostasis model assessment-estimated insulin resistance (HOMA-IR) is an independent predictor of cardiovascular disease (CVD) in type 2 diabetes. RESEARCH DESIGN AND METHODS—Conventional CVD risk factors (sex, age, smoking, plasma lipids, blood pressure, and metabolic control) and insulin resistance (estimated by HOMA) were evaluated at baseline in 1,326 patients with type 2 diabetes examined within the Verona Diabetes Complications Study. At baseline and after a mean follow-up of 4.5 years, CVD was assessed by medical history, physical examination, electrocardiography, and echo-Doppler of carotid and lower limb arteries. Death certificates and medical records of subjects who died during the follow-up were carefully scrutinized to identify cardiovascular deaths. In statistical analyses, CVD was an aggregate end point including both fatal and nonfatal coronary, cerebrovascular, and peripheral vascular disease as well as ischemic electrocardiographic abnormalities and vascular lesions identified by echo-Doppler. RESULTS—At baseline, 441 subjects were coded positive for CVD (prevalent cases). Incident cases numbered 126. Multiple logistic regression analyses showed that, along with sex, age, smoking, HDL/total cholesterol ratio, and hypertension, HOMA-IR was an independent predictor of both prevalent and incident CVD. A 1-unit increase in (log)HOMA-IR value was associated with an odds ratio for prevalent CVD at baseline of 1.31 (95% CI 1.10–1.56, P = 0.002) and for incident CVD during follow-up of 1.56 (95% CI 1.14–2.12, P < 0.001). CONCLUSIONS—HOMA-IR is an independent predictor of CVD in type 2 diabetes. The improvement of insulin resistance might have beneficial effects not only on glucose control but also on CVD in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Self-citationSteinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., & Baron, A. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118709 · Cited by 1,687 · cited 1×
“These potentially antiatherogenic properties of insulin seem to be impaired in insulin-resistant states such as type 2 diabetes (44,45), and this might contribute to explain our results.”
ResultDiabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
Kannel, W. B., & McGee, D. L. (1979) · Diabetes Care · doi:10.2337/diacare.2.2.120 · Cited by 1,203 · cited 1×
“Therefore, it is not surprising that the risk of coronary heart disease (CHD), cerebrovascular disease, and peripheral vascular disease is severalfold increased in type 2 diabetes (2) and that CVDs, as a group, represent the leading cause of death in type 2 diabetes (3).”
BackgroundImpaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
Emoto, M., Nishizawa, Y., Maekawa, K., Hiura, Y., Kanda, H., Kawagishi, T., Shoji, T., Okuno, Y., & Morii, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.818 · Cited by 457
Physical activity and risk for cardiovascular events in diabetic women
Hu, F. B., Stampfer, M. J., Solomon, C., Liu, S., Colditz, G. A., Speizer, F. E., Willett, W. C., & Manson, J. E. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00009 · Cited by 424
Insulin resistance and coronary artery disease
Bressler, P., Bailey, S. R., Matsuda, M., & DeFronzo, R. A. (1996) · Diabetologia · doi:10.1007/s001250050581 · Cited by 226
Bonora, E., Kiechl, S., Oberhollenzer, F., Egger, G., Bonadonna, R. C., Muggeo, M., & Willeit, J. (2000) · Diabetologia · doi:10.1007/s001250050024 · Cited by 140
Self-citation
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640
Jelleyman, C., Yates, T., O'Donovan, G., Gray, L. J., King, J. A., Khunti, K., & Davies, M. J. (2015) · Obesity Reviews · doi:10.1111/obr.12317 · Cited by 588
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Metadata
- Authors
- Bonora, E., Formentini, G., Calcaterra, F., Lombardi, S., Marini, F., Zenari, L., Saggiani, F., Poli, M., Perbellini, S., Raffaelli, A., Cacciatori, V., Santi, L., Targher, G., Bonadonna, R., & Muggeo, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-07-01
- Volume
- 25
- Issue
- 7
- Pages
- 1135-1141
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2101725562
- Cited by
- 604
- References
- 10
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
